Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.4%

4 terminated/withdrawn out of 23 trials

Success Rate

82.6%

-3.9% vs industry average

Late-Stage Pipeline

43%

10 trials in Phase 3/4

Results Transparency

26%

5 of 19 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

8(44.4%)

Phase 2

4(22.2%)

N/A

2(11.1%)

Phase 1

2(11.1%)

Phase 4

2(11.1%)

18Total

Phase 3(8)

Phase 2(4)

N/A(2)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT03544866Completed

The Impact of Pediatric Skin Disorders: The "Big" Study

Role: collaborator

NCT00346294Phase 4Completed

An Open-Label Study to Assess the Rate of Failure of an Enbrel® (Etanercept) SureClick™ Auto-injector in Subjects With Rheumatoid Arthritis

Role: collaborator

NCT00078806Phase 3Terminated

Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis

Role: collaborator

NCT00205231Not ApplicableCompleted

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

Role: collaborator

NCT00038870Not ApplicableWithdrawn

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

Role: collaborator

NCT00201812Phase 1Completed

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Role: collaborator

NCT00201838Phase 1Completed

Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma

Role: collaborator

NCT01522742Terminated

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

Role: collaborator

NCT00357903Phase 3Completed

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials

Role: collaborator

NCT00017693Phase 2Completed

Recombinant Human IL-4 Receptor Used in Treatment of Asthma

Role: collaborator

NCT00100477Phase 2Completed

Use of Topotecan in Patients With Refractory Acute Leukemia

Role: collaborator

NCT01001208Phase 3Completed

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

Role: collaborator

NCT00035958Phase 2Terminated

Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

Role: collaborator

NCT00078793Completed

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Role: collaborator

NCT00356590Phase 3Completed

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trial 016.0012

Role: collaborator

NCT00356356Phase 3Completed

16.0040 Ankylosing Spondylitis Study

Role: collaborator

NCT00111436Phase 3Completed

Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects

Role: collaborator

NCT00116727Completed

Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Role: collaborator

NCT00116714Completed

Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

Role: collaborator

NCT00132418Phase 4Completed

Study of Enbrel in Rheumatoid Arthritis (RA) Subjects With Comorbid Disorders

Role: collaborator